Expressive writing to address distress in hospitalized adults with acute myeloid leukemia: a pilot randomized clinical trial

• Published in: Journal of psychosocial oncology 2024-09, Vol.42 (5), p.587-603
• Main Authors: Nakatani, Morgan M., Locke, Susan C., Herring, Kris W., Somers, Tamara, LeBlanc, Thomas W.
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Cancer; Changes; Clinical trials; COVID-19; Emotions; Enrollments; Experience; expressive writing; Hospitalization; Intervention; Leukemia; Mental depression; patient-reported outcomes; Patients; Psychological distress; Quality of life; Resilience; supportive care; Trauma; Well being; Writing
• ISSN: 0734-7332; 1540-7586; 1540-7586
• DOI: 10.1080/07347332.2023.2296619

Patients with acute myeloid leukemia (AML) experience significant distress. Expressive writing is an intervention designed to improve well-being by encouraging expression of emotions related to traumatic experiences. Expressive writing has been shown to be generally feasible and effective at improving the cancer experience but has not been examined in patients with recently diagnosed hematologic malignancies. We examined the feasibility of an expressive writing intervention for hospitalized patients with AML receiving induction chemotherapy. Fifteen hospitalized AML patients were randomized to complete expressive writing or neutral prompts. Feasibility was defined as 80% of enrolled subjects completing the study. Participants completed validated questionnaires measuring depression, anxiety, resilience, rumination, and quality of life at baseline, completion of the second and fourth writing exercises, and 3 months after enrollment. Participants also completed post-writing surveys following the writing exercise to reflect on the experience. We enrolled 15 participants and 8 of 15 subjects (53%) completed the study. Due to low enrollment, we examined the pre-to-post intervention changes, rather than comparing results across intervention arms. Pre-to-post intervention changes in the expected direction were seen at the second assessment for depression and resilience, at the fourth assessment for rumination, emotional well-being, and social well-being, and at the 3-month follow-up for anxiety and emotional well-being. Similar changes in patient-reported outcomes were also seen in the control condition. Participants who completed the intervention reported the experience was meaningful and were able to express their deepest thoughts and feelings, more so than participants in the control arm. In our work, the expressive writing intervention was not found to be feasible. The trial was interrupted by the COVID-19 pandemic which likely impacted the feasibility. Future studies should aim to identify ways to make the intervention more accessible, such as developing an electronic application for expressive writing.